We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Vitamin B12 Assays Could Be Missing Anemia

By LabMedica International staff writers
Posted on 24 Dec 2012
A new study suggests that newer competitive-binding luminescence assay (CBLA) tests for measuring cobalamin (vitamin B12) levels may miss more than a third of pernicious anemia cases.

Researchers at Weil Cornell Medical College (New York, NY, USA) wished to examine the sensitivity of CBLA tests for cobalamin. To do so, they used frozen serum samples obtained from 23 untreated pernicious anemia patients (15 with anti-intrinsic factor antibodies and 8 without them). Each patient met five criteria: a low cobalamin level according to a radioisotope-dilution assay, a sufficient volume of the serum used in the radioisotope-dilution assay for additional testing, a clinically expressed cobalamin deficiency, unequivocal proof of pernicious anemia, and a defined anti-intrinsic factor antibody status. Aliquots were tested in three clinical laboratories with the use of different CBLAs.

The results showed that the CBLAs showed false normal values in 6 of 23 (26%), 5 of 23 (22%), and 8 of 23 (35%) serum samples, respectively, as compared with a radioisotope-dilution assay; 5 of the serum samples failed with all three CBLAs. False normal results affected 33%–53% of positive serum samples for anti-intrinsic factor antibodies, but no serum samples that were negative for anti-intrinsic factor antibodies. The activity of anti-intrinsic factor antibodies was nonsignificantly greater in the 9 serum samples with a cobalamin assay error than in the 6 without an error. The study was published on September 6, 2012, as a letter to the editor in the New England Journal of Medicine (NEJM).

“Diagnostic sensitivity of the older microbiologic and radioisotope-dilution assays have been estimated to be about 95%, but since CBLAs have replaced these assays, few studies have compared their sensitivity and specificity with older methods,” concluded study authors Ralph Carmel, MD, and Yash Pal Agrawal, PhD. “The diagnostic failures with all three CBLAs suggest widespread CBLA malfunction. Some speculate that these failures have something to do with the newer tests being unable to inactivate serum anti-intrinsic factor antibodies, which can confound test results.”

Related Links:
Weil Cornell Medical College



Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.